logo
logo

Mablink Bioscience Announces A €31 Million Series A Funding Round Led By Sofinnova Partners And Mérieux Equity Partners

Oct 14, 2022•almost 3 years ago

Amount Raised

€31 Million

Round Type

series a

LyonTherapeuticsBiotechnologyHealth Care

Description

LYON, FRANCE / October 14, 2022 / Mablink Bioscience ("Mablink"), a biotechnology company aiming to transform cancer therapy using next-generation antibody-drug conjugates (ADCs), announced today that it has raised a €31 million Series A funding round to advance its lead candidate to the clinic and to build a pipeline of ADCs using its proprietary platform technology. The round was led by Sofinnova Partners and Mérieux Equity Partners, with participation from existing investors.

Company Information

Company

Mablink Bioscience

Location

Lyon, Auvergne Rhône Alpes, France

About

Mablink Bioscience is a French-based biotechnology company specialized in the development of an emerging class of cancer drugs, called antibody-drug conjugate (ADC). Mablink leverages its patented hydrophilic technology PSARlink™ that enables the design of homogenous, plasma-stable next generation ADCs with high DAR, whilst retaining excellent pharmacological properties, in order to quickly bring new and better treatment options to cancer patients.

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech